History & Overview Annual Report President's Pages Center News Community Affairs
Make a Gift Yankees Universe Fund Fred's Team Cycle for Survival Thomas Blake Sr. Memorial Research Fund Donating Blood & Platelets Volunteering Thrift Shop Park Avenue Potluck Cookbook
Press Releases Information for Journalists News@MSKCC
Manhattan New Jersey Long Island Westchester
Working at Memorial Sloan-Kettering Work Sites College Recruitment About Nursing Job Fairs & Career Days Job Search & Apply Online
Making an Appointment
Flash Player is required to view this video.
CancerSmart Web Cast
May 3, 2007 -- Drs. Carol Brown, Nadeem Abu-Rustum, and Paul Sabbatini present, "What You Should Know About the Screening and Treatment of Gynecologic Cancers."
Run time: 71 minutes.

When ovarian cancer is diagnosed early, before it has spread (called stage IA disease), the long-term survival rate exceeds 95 percent. The majority of women with stage IA disease are cured with surgery alone. The problem is that there are no effective methods currently available to screen for epithelial ovarian cancer in the general population so many patients are diagnosed with more-advanced disease.

Having an annual gynecologic pelvic examination will increase the likelihood that an ovarian tumor is discovered, but small ovarian tumors are difficult to detect. The Pap test, performed during the annual pelvic exam, can detect precancers years before cervical cancer develops, but unfortunately is not an effective test for finding ovarian cancer.

For these reasons, identifying an accurate method to detect early-stage ovarian cancer could improve cure rates significantly, saving thousands of women's lives each year.

If a woman experiences any new symptoms -- such as bloating, pelvic or abdominal pain, difficulty eating or feeling full quickly, or urinary symptoms (urgency or frequency) -- on a daily basis for more than two to three weeks, she should be checked by a healthcare professional. For more information on the symptoms of ovarian cancer, visit that section of this cancer information overview.

Ovarian Cancer Screening & Prevention Program

Our Screening Guidelines
Our Screening Guidelines
Our recommendations for ovarian cancer screening

One of our major research goals at Memorial Sloan-Kettering is to improve the methods available to help women determine if they are at risk of developing ovarian cancer, and if they are at high risk, to find ways of reducing risk of disease. The Ovarian Cancer Screening & Prevention Program was established for women with an increased risk for developing ovarian cancer because of a strong family history of breast cancer, ovarian cancer, or both -- or because they are carriers of genes that predispose them to ovarian cancer.

Women who meet certain criteria for being at high risk for ovarian cancer may be offered genetic counseling. They may also be offered screening that includes transvaginal ultrasound (an imaging technique involving the insertion of a special imaging wand into the vagina to identify tumors) and blood tests for the CA-125 protein (which has been shown to be a tumor marker for ovarian cancer). Investigational programs are underway to test the value of measuring newer serum markers and imaging technologies.

For further information about this screening program, call 212-434-5124.

A New Direction for Research: Protein Analysis

One technology that is in its early stages is a blood test developed by investigators at the National Cancer Institute and the FDA. The test seeks patterns in the proteome -- the tens of thousands of proteins circulating in the bloodstream. Using a Web-based artificial intelligence program, scientists analyzed hundreds of millions of possible combinations to draw a cancer's proteomic profile. Research is still underway to determine if this test can be applied to all patients.


Last Updated: Jan. 2, 2008
PrintEmail This Page